Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis.

Abstract

The aim of this study was to evaluate the effects of antiviral therapy on liver stiffness measurement (LSM). Two hundred HBV patients were enrolled from four hospital centers in southern Italy; median age was 50.7 (25-75) males were 68%; 171 patients underwent to liver biopsy and 200 patients had LSM at baseline and 189 at the end of follow-up. One hundred and forty-nine patients were treated with nucleos(t)ide analogs, while 51 patients were untreated. The cutoffs of the LSM, related to the fibrosis stages, were as follows: non-advanced fibrosis≤8.1kPa and advanced fibrosis≥8.2 Kpa. At baseline, the median value of LSM was 14.1kPa for advanced fibrosis/cirrhosis and 6.9kPa for non-advanced fibrosis. LSM was performed at 24months from the start of therapy. The treated patients (68% received Entecavir and 32% Tenofovir) showed a decrease in liver stiffness measurement of 1.5kPa (p<0.001) in non-advanced fibrosis and of 6kPa (p<0.001) in advanced fibrosis/cirrhosis. In the patients not undergoing antiviral treatment, no statistically significant change of the LSM was observed (p=0.26). A logistic binary regression model showed that the only independent factor associated with a significant change in the LSM was the liver stiffness value at baseline (odd ratio 2.855; 95% CI 1.456-5.788; (p=0.007). Long-term antiviral therapy induced a significant reduction of liver stiffness measurement and this result may be related to the reduction of liver fibrosis.